Literature DB >> 8773518

A phase I trial of in vivo gene therapy with the herpes simplex thymidine kinase/ganciclovir system for the treatment of refractory or recurrent ovarian cancer.

C J Link, D Moorman, T Seregina, J P Levy, K J Schabold.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8773518     DOI： 10.1089/hum.1996.7.9-1161

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN： 1043-0342            Impact factor:   5.695


× No keyword cloud information.
  5 in total

1.  DNA methylation of helper virus increases genetic instability of retroviral vector producer cells.

Authors:  W B Young; G L Lindberg; C J Link
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  Psi- vectors: murine leukemia virus-based self-inactivating and self-activating retroviral vectors.

Authors:  K A Delviks; W S Hu; V K Pathak
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 3.  Prodrug/drug sensitivity gene therapy: current status.

Authors:  W R Smythe
Journal:  Curr Oncol Rep       Date:  2000-01       Impact factor: 5.945

Review 4.  CAR-T cell therapy in ovarian cancer: from the bench to the bedside.

Authors:  Xinxin Zhu; Han Cai; Ling Zhao; Li Ning; Jinghe Lang
Journal:  Oncotarget       Date:  2017-08-04

Review 5.  Chimeric Antigen Receptor Design and Efficacy in Ovarian Cancer Treatment.

Authors:  Katarzyna M Terlikowska; Bożena Dobrzycka; Sławomir J Terlikowski
Journal:  Int J Mol Sci       Date:  2021-03-28       Impact factor: 5.923
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.